Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, in 4 years time he is entitled to 4.6M in annual preferred distribution payments. That is about half of today's total revenues. Many much larger company CEO's don't make this with equity options. There is very valid concern around this maneuver until we hear more and see some tangible FDA movement the company has a brighter future so as to not get raked over the coals by management time and time again.
Shorter game, how do? I interpret a somewhat longer. Here's why:
- More versatility with shares to continue funding R&D through stock sales.
- Situation favors partnership vs company sale in near term to test market for product sales.
- 4-yr period before 20% preferred dividend kicks in
None of these point to a shorter game, but I am interested in why you feel otherwise.
Not arguing the case here. Yes you are correct, but some companies are more creative here for their own good.
Freed up...for additional dilution. This means no hope for cash flow positive including R&D for some time.
Not all the time does this hold. I recall an OTC stock a few years ago being creative with an RS. The OS halved, but AS and preferred were untouched. Was a total douche move by management for shareholders.
Except CEO wouldn't have exclusive benefit of 20% preferred dividend that way and fixed warrant price of 0.1521.
I interpret this that it is a shoe in for SequestOx. Roxybond won't compare to SequestOx.
Crazy interesting. I just validated that it is halted. Going to be interesting to see the news.
Just a technical glitch.
Issues will clear up at market open.
Something is odd. In Scottrade I see a pre-market set up bid at 0.28 vs. ask at 0.16. Fake news. :)
Nasrat already stated there is no resubmission fee.
I misunderstood. Was thinking you meant ANDA filings with SunGen, not initiating trials. This is their year end call. Don't they have 90 days after year has ended or is it sooner now that they are an accelerated filer? I was targeting mid to late June. Can't recall exact timing offhand for tiny companies.
Sungen mid-May? Earnings are in June. I'm befuddled by these comments.
Yes, I think those can be expected. But potential market cap without IR is significantly different with just ER options.
I am curious if May results aren't great what the plan B is with IR.
Either way we'll get an update by the Q4 call in June.
Pennies away from the low compared to a 52 week high.
Please let me know the last time Elite has did not hold a quarterly call. There is no reason to believe they will diverge from past practices. Companies don't announce a whole year of CC's all at once. We'll hear a specific date 1-2 weeks before the call when an 8-k is filed.
Fumblings & mistakes along the way at a cost of significant dilution. It cannot be missed.
NDA submissions are pointless without approvals. The proof is in the pudding in 2017.
That is completely inaccurate. Year end call is in June. I would expect an update no later than June, even if results are bad.
Fine for me. I am in the green and just started adding more this year. Company is growing closer by the day to FDA approval of Perc. Going to be an interesting year.
Also, a summary of results is fine for me. If these results aren't good then it may be time for new management as this process for a resubmission of SequestOx has taken far far too long. I'll wait until we hear more before making any judgment. I am expecting a positive outcome early June. I have learned over the years that Nasrat does not under promise & over deliver. Despite Nasrat saying results are expected mid-May, he never accounts for any hiccups in the process and does not build in flexibility. If we hear before the end of May I will be thrilled, but not holding my breath.
If the results are positive in May, the trajectory the stock will be on a rising trajectory and a higher base will form.
Yes, we will all see the results within the next month that will dictate the quality of the company's IR products and quality of it's stock price trajectory.
And yet on the flip side with today's low volume it also says very few are selling at these prices.
That is a ridiculous comment. Current market cap is a definition of a free market for buyers & sellers. Point of transaction signals market cap based on all available info. This is basic finance and economics.
That is old news. Please try providing quotes more recent on the RS.
That is supposition. He didn't say that.
You are right that it may not be imminent. He also said that a reverse split is on the table. If the company can't get to NASDAQ organically the company will get there through other means (e.g., RS)
C-R-O-C-K. No sane certified financial planner would recommend this stock to a client.
LOL I speak fluent French and found that to be hilarious. Wrong, but hilarious.
Doesn't mean much when the product is crap. That only ensures a deteriorated brand from the getgo for current and future product launches.
This company is a never ending joke without a punchline. CEO can't execute well. His strength lies in the BS category.
3 years ago I said this company was a joke and would never make anything here in the US. Nothing has changed. Their product could never compete with ACH, which costs about $0.20/transaction. Banks with a global footprint are re-engineering our financial payments system. Won't be long before both ACH & wire are replaced.
FYI - global footprint includes Africa. This company is built in a wish and a prayer. It simply will not be successful. The technology doesn't differentiate itself enough along with the volume to have decent pricing for any sort of profit.
In another 3 years the company will continue to hose investors and be in the same exact spot. Just watch.
That's what they said about getting to the moon. You don't think there is a way to have chemical reactions take place upon contact with certain substances (e.g., opiates) to react in a certain way? This is not far fetched at all. Don't get me wrong, Elite's tech is great, but far better is being worked on.
It is my hope that if Elite pursues the long-term solo decision, of which I doubt, that they continue to invest beyond their current tech and push the limits.
Let's be realistic, Elite's tech isn't even on the market. They are in development. There is much better tech in development that is working to stem the swallowing issue. Just a matter of time.
But it can be defeated by the highly complex maneuver known as swallowing.